Should you buy, sell or hold Cipla, Fortis Healthcare, Bharti Airtel, BPCL, ONGC shares today?
Brokerages are bullish on celebrity investor Rekha Jhunjhunwala-owned Fortis Healthcare citing the company's good growth outlook. They are divided on telecom stocks such as Bharti Airtel and Indus Towers, and skeptical on energy company stocks such as BPCL and ONGC.
Brokerages are upbeat on Cipla despite the pharma company receiving eight observations from US drug regulator FDA for its Pithampur facility in Madhya Pradesh. They are bullish on Rekha Jhunjhunwala-owned Fortis Healthcare citing the company's good growth outlook, and divided on telecom stocks, such as Bharti Airtel and Indus Towers.
Here's what top brokerages make of some of the key stocks in focus today:
Cipla shares
JPMorgan and Macquarie are upbeat on Cipla. According to the brokerage, the Pitampura unit is one of the company’s key manufacturing facilities besides Goa and the Invagen plant in the US.
Brokerage | Rating | Target price |
JPMorgan | Overweight | Rs 1,210 |
Macquarie | Outperform | Rs 1,215 |
Macquarie points out that Cipla manufactures respiratory products like Proventil Brovana and Pulmicort at the Pithampur plant.
Samvardhana Motherson shares
Jefferies maintains a ‘hold’ rating on Samvardhana Motherson with a target price of Rs 70 per share, as the company’s subsidiary acquires a 100 per cent stake in Germany's SAS Autosystemtechnik, a global provider of cockpit module assembly and logistics services to auto original equipment manufacturers (OEMs).
According to the brokerage, the acquisition will add 10-15 per cent to Motherson’s revenue and EBITDA.
Telecom
Goldman Sachs maintains ‘buy’ on Bharti Airtel and ‘neutral’ on Indus Towers. The brokerage reduces its target price for Bharti Airtel to Rs 870 apiece from Rs 875. It recuced the target for Indus Towers to Rs 200 apiece from Rs 230 per share.
Shriram Finance
Morgan Stanley maintains an ‘overweight’ stance on Shriram Finance with a target price of Rs 1,580 per share citing the company's strong Q3 earnings and fundamentals.
According to the brokerage, the valuation discount to historical mean and to peers has widened. Morgan Stanley expects the stock to rally after supply overhangs.
Fortis Healthcare
Nomura maintains a ‘buy’ call on Fortis Healthcare with a target price of Rs 325 per share as against Rs 319 apiece earlier. The brokerage is positive on traction in the company's hospital business with scope for further improvement, and its investments toward technology upgrades.
Energy space
Nomura is skeptical on energy stocks such as BPCL and ONGC. It has a ‘reduce’ rating each on the stock with target prices of Rs 295 and Rs 120 per share.
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Senior Citizen Latest FD Rates: Know what major banks like SBI, PNB, Canara Bank, HDFC Bank, ICICI Bank are providing on fixed deposits
Gratuity Calculator: Rs 38,000 as last-drawn basic salary, 5 years and 5 months of service; what will be gratuity amount?
EPFO Pension Schemes: Early pension, retirement pension, nominee pension and 4 other pension schemes that every private sector employee should know
Top 5 Small Cap Mutual Funds with best SIP returns in 1 year: See how Rs 25,000 monthly investment has grown in each scheme
Top 7 SBI Mutual Funds With Best SIP Returns in 1 Year: Rs 25,000 monthly SIP investment in No.1 fund has jumped to Rs 3,58,404
10:22 AM IST